These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 3566851)

  • 1. Electrophysiologic effects of asocainol, a new antiarrhythmic agent with predominant class I action.
    Thale J; Gülker H; Hagemense B; Rose D; Haverkamp W; Frenking B
    Arzneimittelforschung; 1987 Jan; 37(1):14-6. PubMed ID: 3566851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the antiarrhythmic profile of the new class I agent diprafenone.
    Gülker H; Thale J; Olbing B; Heuer H; Frenking B; Bender F
    Arzneimittelforschung; 1985; 35(9):1387-93. PubMed ID: 4084340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the electrophysiologic, antiarrhythmic and haemodynamic profile of a new isoquinolinedione derivative.
    Gülker H; Spyra W; Thale J; Krimphove F; Hübner A; Bender F
    Arzneimittelforschung; 1987 Aug; 37(8):917-9. PubMed ID: 3675686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate (SUN 1165), a new antiarrhythmic agent: effects on cardiac conduction.
    Hidaka T; Hamasaki S; Aisaka K; Ishihara T; Morita M; Toyama J; Yamada K
    Arzneimittelforschung; 1985; 35(9):1381-6. PubMed ID: 4084339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
    Bril A; Gout B; Bonhomme M; Landais L; Faivre JF; Linee P; Poyser RH; Ruffolo RR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):637-46. PubMed ID: 8632331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asocainol, a new antiarrhythmic drug with natrium- and calcium-antagonistic effects on ventricular myocardium.
    Späh F
    J Cardiovasc Pharmacol; 1984; 6(6):1027-35. PubMed ID: 6084758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrophysiologic, haemodynamic and antiarrhythmic effects of the new class Ic agent 1-(2'-biphenyloxy)-2-tert.-butylamino-propanol-2-hydrochloride.
    Chiladakis I; Hindricks G; Haverkamp W; Vogt J; Gülker H
    Arzneimittelforschung; 1989 Sep; 39(9):1130-2. PubMed ID: 2590263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic, hemodynamic and cardiac electrophysiological evaluation of N-(2,6-dimethylphenyl)-N'-[3-(1-methylethylamino)propyl]urea (Wy-42,362).
    Bergey JL; Sulkowski T; Much DR; Wendt RL
    Arzneimittelforschung; 1983; 33(9):1258-68. PubMed ID: 6685506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrophysiological profile of the antiarrhythmic compound asocainol studied on perfused guinea-pig hearts and on isolated cardiac preparations.
    Langenfeld H; Haverkampf K; Antoni H
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Jun; 326(2):155-62. PubMed ID: 6472493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Electrophysiologic and hemodynamic effects of the new anti-arrhythmia agent diprafenone].
    Gülker H; Heuer H; Thale J; Behrenbeck T
    Z Kardiol; 1987 Jul; 76(7):411-4. PubMed ID: 3673162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs.
    Shiroshita-Takeshita A; Sakabe M; Haugan K; Hennan JK; Nattel S
    Circulation; 2007 Jan; 115(3):310-8. PubMed ID: 17224477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499].
    Lynch JJ; Wallace AA; Stupienski RF; Baskin EP; Beare CM; Appleby SD; Salata JJ; Jurkiewicz NK; Sanguinetti MC; Stein RB
    J Pharmacol Exp Ther; 1994 May; 269(2):541-54. PubMed ID: 7802864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiologic effects of intravenous E-4031, a novel class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias.
    Fujiki A; Tani M; Mizumaki K; Shimono M; Inoue H
    J Cardiovasc Pharmacol; 1994 Mar; 23(3):374-8. PubMed ID: 7515979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of amiodarone on cardiac electrophysiology in right ventricular rapid pacing-induced heart failure dogs.
    Zhou SX; Zhang XM; Wu W; Chen XC
    Zhongguo Yao Li Xue Bao; 1998 Jul; 19(4):363-8. PubMed ID: 10375786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophysiological effects of penticainide in the anaesthetized dog.
    Sassine A; Brugada J; Munoz A; Romero-Ayala L; Masse C
    Drugs Exp Clin Res; 1987; 13(1):15-20. PubMed ID: 3595440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Class III antiarrhythmic action linked with positive inotropy: antiarrhythmic, electrophysiological, and hemodynamic effects of the sea-anemone polypeptide ATX II in the dog heart in situ.
    Platou ES; Refsum H; Hotvedt R
    J Cardiovasc Pharmacol; 1986; 8(3):459-65. PubMed ID: 2425158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac electrophysiologic and antiarrhythmic actions of 3,4-dihydro-1'-[2-(benzofurazan-5-yl) ethyl]-6-methanesulfonamidospiro [(2H)-1-benzopyran-2,4'-piperidin]-4-one HCl (L-691,121), a novel class III agent.
    Lynch JJ; Wallace AA; Van der Gaag LH; Baskin EP; Bear CM; Gehret JR; Kothstein T; Stupienski RF; Appleby SD; Sanguinetti MC
    J Pharmacol Exp Ther; 1993 May; 265(2):720-30. PubMed ID: 8496818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ischaemia-induced loss or reversal of the effects of the class I antiarrhythmic drugs on vulnerability to fibrillation.
    Aupetit JF; Loufoua-Moundanga J; Faucon G; Timour Q
    Br J Pharmacol; 1997 Feb; 120(3):523-9. PubMed ID: 9031759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarrhythmic, electrophysiologic and hemodynamic effects of ACC-9358.
    Brown BS; Calzadilla SV; Diemer MJ; Hartman JC; Reynolds RD
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1225-34. PubMed ID: 3694532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.